PRESS RELEASES
2024-03-20 16:57
Statement from the Board of Directors of Lipum regarding the mandatory public offer from Flerie Invest AB
The Board of Directors of Lipum AB (publ) (“Lipum” or the “Company”) unanimously recommends the shareholders of Lipum not to accept...
2024-03-19 08:30
LIPUM REPORTS FIRST PATIENT INCLUDED IN THE ONGOING PHASE I CLINICAL STUDY WITH SOL-116
Lipum announces that the first patient with rheumatoid arthritis (RA) has been enrolled and dosed with SOL-116 or placebo in the ongoing phase I clinical...
2024-03-06 19:20
Lipum AB (publ) comment on mandatory bid from Flerie Invest AB
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...
2024-03-04 08:00
Lipum AB (publ) informs that Flerie Invest AB has passed the threshold for a mandatory bid
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...
2024-02-29 08:55
Lipum AB – Year-end report 2023
Lipum AB (publ) has published the interim and the year-end report for 2023. Below is a summary, a complete report (only in Swedish) is available on the...
2024-02-29 08:45
Lipum advances SOL‑116 into phase 2 and carries out a rights issue of up to approximately SEK 187 million at a subscription price of SEK 6.70 per share
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-02-13 13:00
Lipum to participate in following upcoming
Lipum (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced...
2024-01-29 18:30
Lipum reports positive interim results from clinical phase 1 study showing that SOL-116 reduces plasma BSSL levels in healthy subjects
Lipum AB (publ) announces that the first part of the clinical phase 1 study, where healthy subjects received a single dose of the drug candidate SOL-116...
Lipum AB (publ), which has developed the biological drug candidate SOL-116 for treatment of chronic inflammatory diseases such as rheumatoid arthritis...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2024. In accordance with the decision at the Annual...